EcoDrugPlus

Beta-2 Adrenergic Receptor

Ensembl ID : ENSPFOG00000020338
Gene Symbol: LOC103145981
3 Cross references
196 Possible Orthologues:

Beta-2 Adrenergic Receptor-Like

Ensembl ID : ENSPFOG00000020975
Gene Symbol: LOC103154058
3 Cross references
195 Possible Orthologues:

Beta-Secretase 1

Ensembl ID : ENSPFOG00000007323
Gene Symbol: BACE1
3 Cross references
218 Possible Orthologues:

Bradykinin Receptor B1

Ensembl ID : ENSPFOG00000020553
Gene Symbol: BDKRB1
1 Cross references
147 Possible Orthologues:

Bradykinin Receptor B2

Ensembl ID : ENSPFOG00000018721
Gene Symbol: BDKRB2
4 Cross references
245 Possible Orthologues:

Bradykinin Receptor B2

Ensembl ID : ENSPFOG00000020552
Gene Symbol: BDKRB2
2 Cross references
161 Possible Orthologues:

Camp-Specific 3',5'-Cyclic Phosphodiesterase 4b

Ensembl ID : ENSPFOG00000008210
Gene Symbol: LOC103140006
2 Cross references
224 Possible Orthologues:

Camp-Specific 3',5'-Cyclic Phosphodiesterase 4c-Like

Ensembl ID : ENSPFOG00000012025
Gene Symbol: LOC103136427
3 Cross references
193 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1c Subunit

Ensembl ID : ENSPFOG00000004253
Gene Symbol: CACNA1C
1 Cross references
213 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1d Subunit, A

Ensembl ID : ENSPFOG00000018820
Gene Symbol: CACNA1DA
1 Cross references
211 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1f Subunit

Ensembl ID : ENSPFOG00000002258
Gene Symbol: CACNA1FB
1 Cross references
177 Possible Orthologues:

Calcium Channel, Voltage-Dependent, N Type, Alpha 1b Subunit, A

Ensembl ID : ENSPFOG00000007325
Gene Symbol: CACNA1BA
1 Cross references
219 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).